Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ICMT | O60725 | 5/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154096 | 0.84 | RXRA (0.49) | IDO1P2RX7NTRK1POLQSLC6A2 | |
| SCHEMBL5724255 | 0.83 | MPO (0.51) | IDO1P2RX7KCNN4NTRK1POLQ | |
| SCHEMBL28214649 | 0.81 | ICMT (0.40) | ICMTPOLQRXRARXRBRXRG | |
| SCHEMBL9892664 | 0.81 | CHRM5 (0.41) | IDO1ICMTP2RX7KCNN4 | |
| SCHEMBL24875503 | 0.79 | EPHX2 (0.43) | IDO1P2RX7NTRK1POLQSLC6A2 | |
| SCHEMBL1115079 | 0.78 | MAPK8 (0.52) | ICMTSLC6A4MPO | |
| SCHEMBL1395805 | 0.77 | POLQ (0.55) | IDO1POLQHDAC3HDAC1HDAC2 | |
| SCHEMBL6862285 | 0.76 | ALDH1A1 (0.44) | P2RX7POLQ | |
| SCHEMBL21403423 | 0.76 | IDO1 (0.46) | IDO1P2RX7NTRK1POLQSLC6A2 | |
| SCHEMBL295918 | 0.76 | IDO1 (0.50) | IDO1P2RX7NTRK1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805214-B1 | JAK3 SELECTIVE INHIBITOR | UNIV PEKING SHENZHEN GRADUATE SCHOOL (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-11578060-B2 | JAK3 selective inhibitor | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-02-14 | — | — | US | disclosed |
| US-11578060-B2 | JAK3 selective inhibitor | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-02-14 | — | — | US | disclosed |
| CN-110551103-B | JAK3 selective inhibitor | 北京大学深圳研究生院 | 2022-08-23 | — | — | CN | disclosed |
| US-20210214344-A1 | JAK3 SELECTIVE INHIBITOR | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214344-A1 | JAK3 SELECTIVE INHIBITOR | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805214-A1 | JAK3 SELECTIVE INHIBITOR | Peking University Shenzhen Graduate School (CN) | 2021-04-14 | — | — | EP | disclosed |
| CN-110551103-A | JAK3 selective inhibitor | SHENZHEN GRADUATE SCHOOL PEKING UNIV | 2019-12-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214344-A1 | JAK3 SELECTIVE INHIBITOR | JAK3, JAK1, JAK2 | IDO1 1380/4885ICMT 3422/4885P2RX7 1912/4885 |
| US-11578060-B2 | JAK3 selective inhibitor | JAK3, JAK1, JAK2 | IDO1 1380/4885ICMT 3422/4885P2RX7 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.